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Abstract
Purpose We investigated the relationship between three-
dimensional volumetric data of the metabolically active
tumour volume assessed using [
11C]-methionine positron
emission tomography (MET-PET) and the area of
gadolinium-diethylenetriaminepentaacetic acid (Gd-DTPA)
enhancement assessed using magnetic resonance imaging
(MRI) in patients with recurrent glioblastoma (GBM).
Material and methods MET-PET and contrast-enhanced
MRI with Gd-DTPA were performed in 12 uniformly
pretreated patients with recurrent GBM. To calculate the
volumes in cubic centimetres, a threshold-based volume-of-
interest (VOI) analysis of the metabolically active tumour
volume (MET uptake indexes of ≥1.3 and ≥1.5) and of the
area of Gd-DTPA enhancement was performed after
coregistration of all images.
Results In all patients, the metabolically active tumour
volume as shown using a MET uptake index of ≥1.3 was
larger than the volume of Gd-DTPA enhancement (30.2±
22.4 vs. 13.7±10.6 cm
3; p=0.04). Metabolically active
tumour volumes as shown using MET uptake indexes of
≥1.3 and ≥1.5 and the volumes of Gd-DTPA enhancement
showed a positive correlation (r=0.76, p=0.003, for an
index of ≥1.3, and r=0.74, p=0.005, for an index of ≥1.5).
Conclusion The present data suggest that in patients with
recurrent GBM the metabolically active tumour volume
may be substantially underestimated by Gd-DTPA enhance-
ment. The findings support the notion that complementary
information derived from MET uptake and Gd-DTPA
enhancement may be helpful in developing individualized,






To date, the treatment of glioblastoma multiforme (GBM)
remains a major challenge in clinical neurology because of its
invasive characteristics. Infiltrative growing cells, which
cannot be surgically extirpated in toto, are widely held to be
responsible for recurrence of the tumour [1]. Currently,
anatomical imaging using magnetic resonance imaging
(MRI) is the most widely accepted method of determining
the target for treatment. The area of gadolinium-
diethylenetriaminepentaacetic acid (Gd-DTPA) enhancement
is generally assumed to correspond well to the main mass of
active tumour tissue. However, neuropathology has demon-
strated that glioma cells are commonly found beyond the
area of Gd-DTPA enhancement, particularly in GBM [2, 3].
Contrast enhancement depends on blood–brain barrier
damage. Necrosis induced by therapy or occurring sponta-
neously during tumour progression may also show contrast
enhancement and hence cannot be distinguished reliably
from a solid tumour after therapy [4]. Therefore, imaging of
the effectiveness of anticancer therapy by assessing the
extent of MRI contrast enhancement is limited by the lack
of distinction between tumour extent and contrast-
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may be substantially reduced by dexamethasone [5, 6]
which is often necessary to reduce oedema in progressing
tumours and thus modulates the applicability of contrast
enhancement as an indicator of therapeutic efficiency. The
fact that morphological imaging often does not adequately
reflect the underlying tumour biology and its metabolic
activityimposes a considerabledemandtodevelopalternative
biological markers for the therapeutic response.
The use of positron emission tomography (PET), an
imaging technique providing metabolic data, may help
improve diagnostic procedures in the management of
malignant glioma. In PET studies, the radiotracer [
11C]-
methionine (MET) is the most widely used amino acid for
brain tumour evaluation. MET-PETappears to be a valuable
tool for defining the boundaries of malignant gliomas [7]
and may thus help to refine individualized treatment
strategies and the monitoring thereof.
Accumulation of MET is largely due to carrier-mediated
transport, which is not altered by dexamethasone [8] and
permits distinction between tumours and contrast-
enhancing necrosis [9, 10]. MET is transported by the
LAT1 amino acid transporter, which is highly expressed in
cultured cells and malignant tumours [11, 12]. It undergoes
complex metabolism and is incorporated into proteins;
therefore, increased uptake may reflect the metabolic needs
of brain tumours [13].
Previous PET studies in malignant gliomas have sug-
gested that MET-PET allows an earlier and more accurate
assessment of the tumour extent than contrast enhancement
on CT and MRI alone [7, 14, 15]. For example, previous
imaging data revealed that in patients with an untreated
high-grade glioma the area of MET uptake as assessed
using PET is larger than the area of Gd-DTPA enhancement
delineated by MRI [16, 17]. Data assessment in these
studies was, however, based upon a comparison of the
maximal extent of the MET-PET uptake and Gd-DTPA
enhancement, respectively, rather than a truly three-
dimensional based volumetric assessment. A three-
dimensional assessment of the active tumour volume may
contribute, however, to improving the tailoring of a
neurosurgical or radiotherapeutic intervention [18]. Addi-
tionally, complicated cranial neuronavigation procedures
can be facilitated by three-dimensional information of the
tumour extent [19].
We accordingly investigated the relationship between
three-dimensional volumetric data of the metabolically active
tumour volume and the area of Gd-DTPA enhancement in
patients with recurrent GBM using a threshold-based volume
of interest (VOI). We hypothesized that a volumetric
assessment of MET-PET data may help to detect additional
subareas of active tumour volume, over and above the
information provided by Gd-DTPA enhancement alone.
Material and methods
We examined 12 patients (five women and seven men;
mean age 58±10 years, median 62 years, range 41–
73 years) with recurrent glioblastoma who had been
previously treated with a uniform standard therapy regimen
[20] consisting of maximal neurosurgical resection (if
possible), followed by concomitant radiation therapy with
temozolomide (maximum radiation dose 60 Gy; 75 mg
temozolomide per square metre of body surface area per
day, 7 days per week from the first to the last day of
radiotherapy), and initiation of adjuvant temozolomide
chemotherapy (150–200 mg temozolomide per square
Table 1 Patient characteristics and treatment









1 68 F Parietal R + + + 1
2 53 M Corpus callosum R + + + 2
3 65 F Temporoparietal R + + + <1
4 49 M Temporal L + + + 1
5 41 F Temporoparietooccipital L − ++3
6 66 M Parietooccipital R + + + 1
7 65 M Temporoparietal L + Radiotherapy alone + 26
8 44 M Frontal L + + − 4
9 50 F Temporoparietal L + + + <1
10 58 M Temporoparietal L − ++< 1
11 72 M Temporal R + Radiotherapy alone + 1
12 64 F Occipital L + + + 1
Eur J Nucl Med Mol Imaging (2010) 37:84–92 85metre of body-surface area over 5 days, repeated every
23 days; see Table 1). The diagnosis was confirmed
histologically before initiating therapy. Due to a close
localization of the tumour and eloquent brain areas or
inoperability, in two patients neurosurgical resection could
notbeperformed(patients5and10).Basedontemozolomide-
related side effects (bone marrow depression), in two patients
radiationtherapywasperformedalone(patients7and11),and
in one patient adjuvant temozolomide chemotherapy could
not be continued (patient 8).
Recurrence of the glioblastoma was defined according to
the Macdonald criteria (gadolinium enhancement or tumour
enlargement ≥25%) with corresponding clinical deterioration
[21]. The time to progression (TTP), defined as the time in
months between initiation of the standard GBM therapy and
tumour recurrence according to the Macdonald criteria, was
determined.
MET-PET studies were performed in close temporal
association with confirmation of the diagnosis “recurrent
glioblastoma”. All patients gave written consent to partic-
ipating in the MET-PET studies. PET studies were
performed on an ECAT EXACT or ECAT EXACT HR
scanner (Siemens/CTI, Knoxville, TN). Following a 10-min
transmission scan, PET scans were performed after slow
intravenous bolus injection of 740 MBq (20 mCi) of MET,
synthesized according to the method of Berger et al. [22].
Tracer accumulation was recorded in three-dimensional
mode over 60 min in 47 transaxial slices covering the entire
brain. Summed activity from 20 to 60 min after tracer
injection was used for image reconstruction. Images were
reconstructed with Fourier rebinning and filtered back-
projection with a ramp filter. Images were corrected for
scatter, attenuation and random coincidences. Spatial
resolution was 6 mm or better in all dimensions.
The MRI scan (1.5 T) was performed using a Gyroscan
Intera scanner (Philips Medical Systems) and images were
acquired using a standard head coil. Axial T1-weighted
images were obtained from the second cervical vertebral
body to the vertex. To provide a precise coregistration and
accurate volume calculation, slice thickness was adjusted to
1 mm. After intravenous administration of Gd-DTPA
(0.1 mmol/kg body weight), axial T1-weighted images
were obtained using standard procedures.
PET data were evaluated by a region of interest (ROI)
analysis. As described previously [8], a circular ROI (8 mm
radius, surface area 201 mm
2) was placed in the hottest area
of the tumour (i.e. centred on the pixel with maximal
activity). For reference, an identically sized circular ROI
was placed on the unaffected corresponding contralateral
cortex, or, if impossible because of the tumour location, on
intact brain regions. The same procedure was performed
with an approximately fourfold larger, irregularly shaped
reference ROI (median surface area 838±26 mm
2) placed
Fig. 1 After coregistration of MR- and MET-PET images, a circular
ROI (red circle, 8 mm radius, surface area 201 mm
2) is placed in the
hottest area of the tumour. For reference, an identical ROI (white
circle, central image) and a larger irregularly shaped ROI (white
irregular shape, bottom image, surface area 809 mm
2 in this example)
are placed on the unaffected contralateral cortex
86 Eur J Nucl Med Mol Imaging (2010) 37:84–92on the unaffected contralateral cortex to rule out systematic
error, e.g. due to a partial volume effect in a smaller,
identically sized reference ROI (Fig. 1). The tumour-to-
contralateral mean activity ratio with both types of
reference ROIs was calculated as an uptake index.
Tumour volumes were measured by performing a three-
dimensional thresholding based VOI analysis in all patients
for MET-PET uptake and contrast-enhanced lesions on
MRI, respectively, using the VINCI tool, developed in-
house [23]. The threshold for increased MET uptake was
set to ≥1.3 in the contiguous tumour region. In a previous
study with mainly high-grade gliomas comparing the exact
local MET uptake with histology of stereotaxically guided
biopsies, a receiver operating characteristics analysis
demonstrated a sensitivity of 87% and specificity of 89%
for the detection of tumour tissue at a threshold of 1.3-fold
MET uptake relative to normal brain tissue [7]. This
threshold was confirmed in a further study using diffusion
tensor imaging in comparison with MET uptake [24]. For
comparison and to rule out false-positive results, the VOI
analysis was also performed with a higher threshold (≥1.5).
T h i st h r e s h o l dh a sb e e ns h o w nt op r o v i d et h eb e s t
separation between tumour and nontumour tissue in low-
grade gliomas [8]. The threshold for positive contrast
enhancement on MRI was determined by varying the value
of the lower threshold to identify and separate the area of
positive enhancement from the tissue with lower intensity.
The PET and MR images of each patient were
coregistered with an accuracy of 2 mm or better using an
automated procedure [25, 26] to ensure precise correspon-
dence of ROI placement and to provide anatomical
comparability of MET PET and MRI.
Descriptive statistics are provided as means and standard
deviation and also as medians and range. The Spearman
correlation test was used to calculate the correlation
coefficient. Statistical analysis was performed using Sigma-
Stat software (SigmaStat version 3.0, SPSS, Chicago, IL).
Results
The mean TTP after initiation of standard therapy was 12.2±
10.1 months (median TTP 8 months, range 4–40 months; see
Table 2). No significant correlations between TTP and
volumes of metabolically active tumour and volumes of
Gd-DTPA enhancement, respectively, were observed.
Table 2 Volumes of metabolically active tumour and Gd-DTPA enhancement with patients ranked according to TTP
Patient no. TTP (months) Active tumour volume (cm
3) Gd-DTPA enhancement volume (cm
3)
MET-PET uptake index ≥1.3 MET-PET uptake index ≥1.5
10 4 15.40 8.76 11.10
1 6 35.88 17.19 24.19
11 7 9.08 5.11 5.23
4 7 19.08 11.98 10.68
9 8 18.60 10.94 7.92
3 8 37.56 19.34 14.37
8 8 39.45 24.87 32.71
6 8 74.81 13.37 14.21
5 13 42.25 34.15 8.6
12 14 5.65 1.09 3.45
7 23 61.13 15.43 32.07
2 40 3.15 1.90 0.21
Mean ± SD 12.2±10.1 30.17±22.40 13.68±9.52 13.7±10.6
Table 3 MET uptake indices and metabolically active tumour volumes using different reference ROIs. Values are means ± SD
Smaller, identically sized reference ROI (8mm radius,
surface area 201mm
2)
Larger, irregular shaped reference ROI (median surface
area 838±26mm
2)
MET uptake index 2.04±0.44 2.04±0.43
Metabolically active tumour (cm
3)
Threshold ≥1.3 30.2±22.4 30.1±22.9
Threshold ≥1.5 13.7±9.5 13.6±9.4
Eur J Nucl Med Mol Imaging (2010) 37:84–92 87Fig. 2 Coregistration of MET-PET and MR images and thresholding of the VOIs (patient 3) shows that the volume of Gd-DTPA enhancement is
less than half the metabolically active tumour volume
88 Eur J Nucl Med Mol Imaging (2010) 37:84–92By using a reference ROI of identical size, the mean MET
uptake index was 2.04±0.44 (median 2.01, range 1.50–2.95).
There was no significant difference in the mean MET uptake
index whenusinganapproximately fourfoldlarger irregularly
shaped reference ROI (mean index 2.04±0.43, median 1.99,
range 1.51–2.95; p>0.05, t-test; see Table 3). The median
surface area of the larger irregularly shaped reference ROI
was 838±26 mm
2 (in contrast, the surface area of the same-
sized ROI was 201 mm
2;s e eF i g .1).
The metabolically active tumour volumes calculated using
three-dimensional VOI analysis and a threshold of ≥1.3 or
≥1.5 were not significantly different between the two types of
reference ROI (p>0.05, t-test; see Table 3). In contrast, the
metabolically active tumour volumes were significantly
larger using a threshold of ≥1.3 than when using a threshold
of ≥1.5 for both types of reference ROI (p=0.05, Mann-
Whitney rank sum test; see Table 3,F i g .3).
As expected in GBM, in all patients the tumours
displayed areas of increased MET uptake and Gd-DTPA
enhancement. The mean metabolically active tumour
volume as shown by a MET uptake index of ≥1.3 was
significantly higher than the mean volume of Gd-DTPA
enhancement (30.2±22.4 vs. 13.7±10.6 cm
3; p=0.04,
Mann-Whitney rank sum test; see Table 2, Fig. 2). In
contrast, when using a MET uptake index of ≥1.5, the
metabolically active tumour volume was not significantly
different from the mean volume of Gd-DTPA enhancement
(13.7±9.5 vs. 13.7±10.6 cm
3; p>0.05, t-test; see Table 2).
Metabolically active tumour volumes as shown using
MET uptake indexes of ≥1.3 and ≥1.5 and the volumes of
Gd-DTPA enhancement showed a positive correlation (r=
0.76, p=0.003, for an index of ≥1.3, and r=0.74, p=0.005,
for an index of ≥1.5; Spearman correlation; see Fig. 3). In
some patients, the location of the Gd-DTPA enhancement
volume did not substantially differ from the location of the
active tumour volume on MET-PET. In contrast, in other
patients the volume of Gd-DTPA enhancement was not
exclusively within the active tumour volume on MET-PET.
On superimposed images, in these patients the volume of
Gd-DTPA enhancement was often eccentric and partially
located outside the active tumour volume on MET-PET (see
Fig. 4). In these patients, especially those with a large Gd-
DTPA enhancing volume, the location of Gd-DTPA
enhancement did not correspond to MET uptake (see
Table 4). The percentage of Gd-DTPA enhancing volume
outside the area of the active tumour volume at a MET
uptake threshold of ≥1.3 is shown for each patient in
Table 4.
Discussion
The use of MET-PET, an imaging technique that provides
metabolic information, may improve the ability of diagnos-
tic procedures to determine the extent of malignant gliomas.
However, to date an accurate three-dimensional comparison
of the volumes of the metabolically active and contrast-
enhanced subareas in patients with recurrent GBM is
lacking. Previous PET studies of patients with untreated
GBM have shown that the two-dimensionally assessed
MET area corresponds well with the area of tumour
extension and, moreover, GBM infiltration may extend
well beyond the area of Gd-DTPA enhancement [16]. The
aims of our study were (1) to compare three-dimensional
metabolic and structural data of Gd-DTPA- and MET-
positive tumour subareas, and (2) to provide evidence for
its clinical significance in patients with recurrent GBM. The
recent development of coregistration techniques for imag-
ing data [23, 26] allows a more accurate integration of
MET-PET metabolic data with MRI anatomical data, which
may help to improve the clinical value of MET-PET
scanning.
Fig. 3 The metabolically active tumour volumes as assessed by MET
uptake indexes of ≥1.3 and ≥1.5 are significantly correlated with the
volumes of Gd-DTPA enhancement
Eur J Nucl Med Mol Imaging (2010) 37:84–92 89Our study shows that there are distinct differences in
volumetric images of recurrent GBM between MET-PET
and MRI, suggesting that in patients with recurrent GBM
the metabolically active tumour volume extends consider-
ably beyond the area of Gd-DTPA enhancement. These
findings are in line with our hypothesis that a volumetric
assessment of MET-PET data is able to detect subareas of
active tumour volume in addition to those derived from Gd-
DTPA enhancement alone.
In this study sample, TTP was within the range reported
previously in mixed adult/elderly GBM patient populations
[20]. The patients received standard therapy according to
the EORTC 26981 study [20], except in two patients in
whom the therapy was varied due to individual constraints,
Fig. 4 MR-, MET-PET and superimposed images of the active
tumour volume (red) at a MET-uptake index threshold of ≥1.3 and
volume of GTPA enhancement (white) in patient 1. Gd-DTPA
enhancement is not always located exclusively within the subareas
of the tumour positive on MET-PET. On superimposed pictures
(bottom), Gd-DTPA enhancement is eccentric and located partially
outside the active tumour volume
Table 4 Fraction of the Gd-DTPA enhancement volume exclusively located outside the active tumour volume






Percentage of Gd-DTPA enhancement volume
outside area of active tumour volume
2 3.15 0.21 <5
12 5.65 3.45 5–10
11 9.08 5.23 5–10
9 18.60 7.92 5–10
5 42.25 8.6 5–10
4 19.08 10.68 10–20
10 15.40 11.10 >20
6 74.81 14.21 10–20
3 37.56 14.37 >20
1 35.88 24.19 >20
7 61.13 32.07 10–20
8 39.45 32.71 >20
90 Eur J Nucl Med Mol Imaging (2010) 37:84–92as detailed in Table 1. These individual constraints reflect
the need for individual tailoring of therapy, e.g. to predict
therapy failure as early as possible before clinical status
deterioration and the appearance of side effects, i.e. bone
marrow suppression, restrict the choice of rescue therapies.
A three-dimensional assessment of the active tumour
volume may be helpful for more precise planning of a
neurosurgical or radiotherapeutic intervention. Additionally,
sophisticated cranial neuronavigation procedures could be
facilitated by knowledge of three-dimensional information
[19]. It has been shown previously, that volume reconstruc-
tion techniques may be used to increase the correlation
between histological and in vivo tumour volume measure-
ments in mouse models of human glioma [27]. Unlike
previous data based upon a two-dimensional assessment of
MET-PET imaging data [16], our noninvasive three-
dimensional analysis of the volume of metabolically active
tumour and the area of Gd-DTPA enhancement may
provide further information as to the spatial configuration
of the active tumour volume in relation to the volume of
Gd-DTPA enhancement. Therefore, MET-PET- and MR-
guided imaging with calculation of the metabolically active
tumour volumes and the volumes of Gd-DTPA enhance-
ment, respectively, may help improve the planning of
specific, location-based tumour recurrence therapy strate-
gies in patients with recurrent GBM (i.e. neurosurgical
resection, focal radiotherapy).
Our data suggest that including MET-PET-derived three-
dimensional information may help delineate more precisely
the tumour extent and may thereby help improve neurosur-
gical resection. In various other recently presented studies,
MET-PET data were successfully combined with MRI data
to provide specific information for defining the target
volume for radiosurgery and neuronavigation surgery in
patients with brain tumours such as meningiomas and high-
grade gliomas [18, 28, 29]. Our findings lend further
support to the notion that MET-PET may provide comple-
mentary information to MRI, and may hence be helpful in
improving future therapy strategies in patients with recur-
rent GBM. For example, in a recent study metabolic
information helped planning of surgery using PET
imaging-guided volumetric resection of high-grade gliomas
[30]. It was demonstrated that complete resection according
to PET tracer uptake in high-grade gliomas increases
survival, whereas complete resection according to MRI
contrast enhancement does not [30]. In this context, studies
comparing the histology in different parts of the tumour and
especially at the operative field margins according to local
MET uptake and MRI enhancement are needed.
Concerning the methodological aspects of our study,
variability in the measurement of the active tumour volume
was exacerbated by using an inappropriately small circular
ROI to determine the background reference level but this
could be reduced by further assessment with an approxi-
mately fourfold larger, irregularly shaped reference ROI,
which produced similar results. Furthermore, for calculation
of the active tumour volumes we used different fixed
thresholds (≥1.3 and ≥1.5) which both revealed significant
correlations with the volume of Gd-DTPA enhancement.
These observed significant correlations stress the validity of
the method to calculate the active tumour volume.
However, two outliers (patients 6 and 7; see Table 2,
Fig. 3) with different active tumour volumes after data
assessment using thresholds ≥1.3 and ≥1.5 were identified.
This observation could be best explained by a relatively
diffuse, widespread MET uptake pattern at the time of
recurrence of GBM indicating highly malignant, infiltrative
growing tumour biology in these patients.
Furthermore, the correlation between Gd-DTPA enhance-
ment and MET uptake suggests that both phenomena are not
independent but may be influenced by common underlying
pathophysiological factors. Whereas in individual patients the
location of Gd-DTPA enhancement volumes did not substan-
tially differ from the location of the active tumour volume on
MET-PET, in other patients Gd-DTPA enhancement volumes
on superimposed images were often eccentric and partially
located outside the active tumour volume on MET-PET. In
these patients, especially those with large Gd-DTPA enhanc-
ing volumes, the location of Gd-DTPA enhancement did not
match MET uptake. In these patients, MR and MET-PET
imaging suggested necrotic tissue in the area of Gd-DTPA
enhancement without MET uptake.
Due to the small number of patients in the current study,
a larger study is needed to confirm the clinical usefulness of
assessing the metabolically active tumour volume by MET-
PET in patients with recurrent GBM. The current study,
however, indicates the potential of MET-PET to more
accurately assess recurrent GBM and opens new perspec-
tives for the management of recurrent GBM. In the future, it
seems likely that the complementary information obtained
with multiple imaging modalities will lead to the most
efficient delineation of the appropriate tumour volume.
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